Nintedanib Stada (Nintedanib)

Nintedanib blocks multiple receptor tyrosine kinases, including VEGFR, FGFR and PDGFR. By inhibiting these receptors, it reduces fibroblast activation and migration, limits new blood‑vessel formation, and curtails the signalling that fuels fibrotic tissue and tumor growth. This multi‑targeted approach underlies its antifibrotic and anti‑angiogenic effects.

The specific dose and dosing schedule of Nintedanib Stada are determined by the prescribing clinician based on the patient’s indication, renal and hepatic function, and overall health status. Healthcare professionals follow the approved labeling and adjust the regimen as needed; patients should follow the exact instructions provided by their prescriber.

Safety data for Nintedanib Stada in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment, and breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Nintedanib Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for IPF is pirfenidone, another antifibrotic agent. While both drugs aim to slow lung function decline, Nintedanib targets a broader range of tyrosine kinases, potentially offering benefit in patients with concomitant vascular involvement. Pirfenidone works mainly through anti‑inflammatory and antioxidant pathways. Choice of therapy depends on individual tolerability, comorbidities and physician judgment.

Nintedanib Stada should be stored at temperatures below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place away from direct heat sources. Do not refrigerate or freeze the tablets, and ensure the container is tightly closed when not in use.

Nintedanib Stada is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water and should be taken at the same time each day to maintain consistent blood levels. Patients must follow the dosing schedule prescribed by their healthcare professional.

The most serious adverse events include severe liver injury (signs such as jaundice or dark urine), major bleeding episodes (e.g., gastrointestinal or intracranial hemorrhage), arterial thromboembolic events (such as stroke or heart attack), and significant hypertension. Patients should seek immediate medical attention if they notice any of these symptoms.

Nintedanib Stada is contraindicated in patients with severe hepatic impairment, those who are pregnant or breastfeeding without a clear benefit, and individuals with a known hypersensitivity to nintedanib or any of the tablet excipients. Caution is also advised for patients with uncontrolled cardiovascular disease, active bleeding disorders, or recent major gastrointestinal surgery.